Bajaj Healthcare Q1 FY27: net profit up 16% to ₹13.7 crore, revenue up 11%
Bajaj Healthcare (BAJAJHCARE) said it has published its Q1 FY27 results, reporting revenue of ₹166 crore (+11.3% year on year), net profit of ₹13.7 crore (+15.8%), earnings per share of ₹4.07. The company is valued at about ₹1,140 crore.
What happened
In a filing with the BSE on 17 October 2026 at 05:40 PM, Bajaj Healthcare (BAJAJHCARE) said that it has published its Q1 FY27 results, reporting revenue of ₹166 crore (+11.3% year on year), net profit of ₹13.7 crore (+15.8%), earnings per share of ₹4.07.
Company snapshot
Bajaj Healthcare is a small-cap company, with a market value of about ₹1,140 crore.
The stock last traded at ₹338.8, against a 52-week range of ₹272.4–₹490 (30.9% below the high).
Before this filing the shares had moved +5.6% over the month and −9.4% over three months. Average daily turnover over the last 20 sessions was about ₹4.98 crore.
Promoters held 58.59% at the end of Q1 FY27, up 0.30% points from the previous quarter. Foreign institutions owned 2.19% and domestic institutions 1.92%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 149 | 11.8 | 3.74 |
| Q2 FY26 | 148 | 11.1 | 3.53 |
| Q3 FY26 | 161 | 15.7 | 4.96 |
| Q4 FY26 | 153 | -22.9 | -7.16 |
| Q1 FY27 | 166 | 13.7 | 4.07 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Market-wide, 9,604 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 17 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Bajaj Healthcare secures NCLT approval for Genrx acquisition
- NCLT Mumbai Allows Bajaj Healthcare To Acquire GENRX Pharmaceuticals
- Bajaj Healthcare Q2 results: Revenue and profit rise, but margins ease
- Bajaj Healthcare: Genrx Pharmaceuticals కొనుగోలుకు NCLT గ్రీన్ సిగ్నల్
- Bajaj Healthcare (NSE:BAJAJHCARE): What Is the Q2 and H1 FY27 Earnings Call About?
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.